Drug Database
AN

antithrombin III (Neuart)

✓ Approved

Mitsubishi Tanabe Pharma Corporation · SERPINC1 · 细胞治疗

什么是 antithrombin III?

antithrombin III 是一种细胞治疗,由Mitsubishi Tanabe Pharma Corporation研发。该药已获批,用于治疗相关适应症。

药物档案

商品名Neuart
公司Mitsubishi Tanabe Pharma Corporation
药物类别细胞治疗
分子靶点SERPINC1
状态Approved

作用机制

分子靶点

antithrombin III 作用于 1 个分子靶点:

SERPINC1serpin family C member 1 (ATIII, AT3D)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

antithrombin III 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersThrombosis✓ Approved

相关研究文献

PubMedCancer discovery2026-10-26

First mRNA Cancer Vaccine Succeeds in Phase III Trial.

Adding the mRNA-based individualized neoantigen vaccine intismeran autogene to the PD-1 inhibitor pembrolizumab following surgery for melanoma reduced the risk of disease recurrence or death by 42%, according to the results of the phase III INTerpath-0001 trial. The data were presented at the ESMO Congress 2026, held October 23-27, in Madrid, Spain.

PMID 42929716
阅读全文 →
PubMedInorganic chemistry2026-10-26

Crystal Morphology of Luminescent Microcrystals Based on Eu(III) Coordination Polymers Changed by Surfactant Solutions.

Enokido Masaki M, Wang Mengfei M, Kitagawa Yuichi Y, Hasegawa Yasuchika Y

The morphological control of Eu(III) coordination polymers with intermolecular interactions between polymer chains was demonstrated with surfactants as molecular modulators. [Eu(hfa)3(m-dpb)]n coordination polymers (hfa; hexafluoroacetylacetonate, m-dpb; 1,3-bis(diphenylphosphoryl)benzene) showed crystal growth in CTAB/SDS solution (CTAB, cetyltrimethylammonium bromide; SDS, sodium dodecyl sulfate). The crystal morphology of [Eu(hfa)3(m-dpb)]n was changed under the synthetic conditions with various types of cationic surfactants (N+(CH3)3CnH2n+1; n = 8, 12, and 16). The Eu(III) coordination polymer crystals were observed as plates and slender rod shapes. Their crystal morphologies suggest that the crystal growth along the chain growth direction is faster than that along the chain stacking direction.

PMID 42929628
阅读全文 →
PubMedInternational journal of cancer2026-10-26

Comments on "Concomitant Use of Proton Pump Inhibitors and Survival Outcomes in Patients Receiving Adjuvant Chemotherapy for Stage III Colon Cancer".

Zhang Xiaoxiang X, Zhang Yu Y

PMID 42928422
阅读全文 →
PubMedInternational journal of cancer2026-10-26

Reply to: Comments on 'Concomitant Use of Proton Pump Inhibitors and Survival Outcomes in Patients Receiving Adjuvant Chemotherapy for Stage III Colon Cancer'.

Loft Matthew M, Gibbs Peter P

PMID 42928504
阅读全文 →
PubMedThe Analyst2026-10-26

A sensitive and visual colorimetric biosensor for liver cancer-associated miRNA using Exo-III assisted target recycling and a cyclization-functional DNAzyme walker.

Zhang Guanchao G, Jia Lei L, Xu Bing B

The accurate detection of liver cancer-associated microRNAs (miRNAs) remains challenging due to their low abundance and high sequence homology. Herein, we report a colorimetric biosensor integrating Exo-III-assisted target recycling with a cyclization-functional DNAzyme walker for sensitive and highly specific miRNA detection. Notably, the assay incorporates two distinct miRNA recognition events: first, the target miRNA hybridizes with a stem-loop probe to trigger Exo-III-mediated cyclic cleavage; second, the released initiator strand activates the DNA walker on magnetic beads, where the miRNA must hybridize with a specific binding site on the tracker strand to reconstitute the split DNAzyme catalytic core. This dual-recognition mechanism dramatically enhances specificity, enabling the sensor to discriminate single- and double-nucleotide mismatches with high reliability. Coupled with Ag+-aptamer-mediated signal transduction, the platform produces a visible color change for naked-eye readout. With cascade amplification, the assay achieves a detection limit of 2.7 fM and a linear range of 5 fM to 100 pM. Successful spike-recovery tests in human serum (96.2-104.4%) suggest its potential for clinical application. This portable, visual colorimetric strategy offers a promising solution for early liver cancer screening.

PMID 42929358
阅读全文 →
PubMedSmall methods2026-10-26

Symmetry-Breaking Polarized Ir-COFs With Ultralow Exciton Binding Energy Enable Directional Charge Allocation for Synergistic Photocatalytic Gold Recovery and BPA Photodegradation.

Chen Yi-Ru YR, Wang Xiu X, Wang Ruixiang R, Li YiBao Y et al.

Synergistic photocatalytic precious metal recovery and organic pollutant degradation promise sustainable resource recovery. However, this process is constrained by high exciton binding energy and disordered carrier migration, inducing charge crosstalk and sluggish kinetics among competing redox centers. A molecular induced polarization symmetry-breaking (MIP-SB) strategy constructs a polarized Ir-functionalized covalent organic framework (COF), BT-mBpyCN2+-Ir, where Ir coordination creates a π-d-π* coupled electronic structure promoting directional ligand-to-ligand charge transfer (LLCT) for efficient charge allocation. This structural design generates a built-in electric field, with Kelvin probe force microscopy (KPFM) showing a surface potential of 120 mV. This strong internal field yields an ultralow exciton binding energy of 24.7 meV and a prolonged carrier lifetime of 1.85 ns. This directional charge allocation enables a mutual promotion effect: the bisphenol A (BPA) degradation rate constant increases by 21-fold in the presence of Au(III), while the Au(III) reduction rate is enhanced by 3.8-fold when BPA co-exists. Consequently, under sacrificial-agent-free conditions, BT-mBpyCN2+-Ir achieves 99.4% BPA degradation within 30 min and a gold extraction capacity of 3145 mg g-1. Density functional theory (DFT) calculations confirm that BPA coexistence lowers the Gibbs free energy for Au(III)-to-Au(0) conversion, revealing a thermodynamically favored dual-channel synergistic mechanism.

PMID 42929171
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多antithrombin III